Rick Lifsitz and Larry Blandford address market access for novel Alzheimer’s treatments in a new commentary for Journal of Clinical Pathways
This case study illustrates a successful program that led to 7 major national health plans offering the manufacturer’s top 2 brands at $0 out-of-pocket to the patient.
Precision for Value’s Dan Renick offers his perspective on GSK’s Breo in The Pink Sheet.
Dan Renick comments on the importance of value demonstration for respiratory disease treatments in The Pink Sheet.
(more…)
Pharma Industry Firm Moves for More Space
Precision for Value, a company that helps bring pharmaceutical products to market, has found a larger home at One Grand Central Place.
ISPOR Annual International Meeting
Precision will be exhibiting in booth 81/82
Location: Washington, D.C.
Los Angeles, May 17, 2016 — Precision Health Economics (PHE), a global leader in health economic research, policy, and analytics, announced today that Peter Neumann, ScD has joined PHE in the role of principal scientific advisor.
Precision’s Chandra and Shafrin Address Value Frameworks in JAMA
In this study, the Precision Health Economics team quantifies how patients value new oncology therapies through research focused on 2 clinical contexts in advanced cancer: metastatic malignant melanoma and metastatic breast cancer.
We are pleased to present the second installment in our recurring column, Pharma Insights. This month we take a look at an interesting twist in how the use of complementary and companion diagnostics is playing out in real-world clinical practice. In a health care system that increasingly seeks to more precisely target therapeutic approaches to diseases, diagnostic testing is the key to unlocking greater value in pharmacotherapy. Two classes of diagnostic tests—companion and complementary diagnostics—have emerged to address this need.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
